Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis

Abstract Background To determine whether initiation of a tumor necrosis factor inhibitor (TNFi) or methotrexate improves hemoglobin A1c in patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ankylosing spondylitis (AS) who also have diabetes mellitus (DM). Methods A retrospective...

Full description

Bibliographic Details
Main Authors: Santhi Mantravadi, Michael George, Colleen Brensinger, Min Du, Joshua F. Baker, Alexis Ogdie
Format: Article
Language:English
Published: BMC 2020-09-01
Series:BMC Rheumatology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s41927-020-00138-3
id doaj-901d1a883d754190b28d81d516299ed7
record_format Article
spelling doaj-901d1a883d754190b28d81d516299ed72020-11-25T02:43:33ZengBMCBMC Rheumatology2520-10262020-09-014111010.1186/s41927-020-00138-3Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritisSanthi Mantravadi0Michael George1Colleen Brensinger2Min Du3Joshua F. Baker4Alexis Ogdie5Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson UniversityDepartment of Medicine, Division of Rheumatology, Perelman School of Medicine, University of PennsylvaniaDepartment of Biostatistics, Epidemiology, and Informatics, Division of Rheumatology, Perelman School of Medicine, University of PennsylvaniaDepartment of Biostatistics, Epidemiology, and Informatics, Division of Rheumatology, Perelman School of Medicine, University of PennsylvaniaDepartment of Medicine, Division of Rheumatology, Perelman School of Medicine, University of PennsylvaniaDepartment of Medicine, Division of Rheumatology, Perelman School of Medicine, University of PennsylvaniaAbstract Background To determine whether initiation of a tumor necrosis factor inhibitor (TNFi) or methotrexate improves hemoglobin A1c in patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ankylosing spondylitis (AS) who also have diabetes mellitus (DM). Methods A retrospective cohort study was conducted in Optum’s de-identified Clinformatics® Data Mart Database, an administrative claims database, using data from 2000 to 2014. Patients with PsA, RA, or AS, with DM (defined by ICD-9-CM codes) and/or HbA1c ≥7%, who newly initiated either a TNFi, MTX, or metformin (positive control) were identified. The change in HbA1c after drug initiation was calculated. Statistical differences in the change in HbA1c between drugs were assessed using the Wilcoxon rank sum test and linear regression models adjusting for potential confounders. Results Among 10,389 drug initiations in 9541 patients with PsA, RA, or AS, and available HbA1c values, HbA1c was ≥7 at baseline in 254 (35%) TNFi initiations, 361(37%) MTX initiations, and 2144 (50%) metformin initiations. Median HbA1c change was − 0.35 (IQR -1.10, 0.30) after TNFi initiation, − 0.40 (IQR -1.20, 0.30) after MTX initiation, and − 0.80 (IQR -1.60, − 0.10) after metformin initiation. In adjusted analyses, TNFi initiators had less of a decrease in HbA1c compared to MTX initiators (β 0.22, 95% CI: 0.004, 0.43), p = 0.046. Metformin initiators had a significantly greater decrease in HbA1c than MTX, β − 0.38 (95% CI: − 0.52, − 0.23), p < 0.001. Glucocorticoid use was not accounted for in the models. Conclusion HbA1c decreased with TNFi initiation or MTX initiation. Reductions in HbA1c after initiation of a TNFi or MTX are about half (~ 0.4 units) the decrease observed after initiation of metformin.http://link.springer.com/article/10.1186/s41927-020-00138-3Psoriatic arthritisRheumatoid arthritisAnkylosing spondylitisDiabetes mellitusOutcomesEpidemiology
collection DOAJ
language English
format Article
sources DOAJ
author Santhi Mantravadi
Michael George
Colleen Brensinger
Min Du
Joshua F. Baker
Alexis Ogdie
spellingShingle Santhi Mantravadi
Michael George
Colleen Brensinger
Min Du
Joshua F. Baker
Alexis Ogdie
Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
BMC Rheumatology
Psoriatic arthritis
Rheumatoid arthritis
Ankylosing spondylitis
Diabetes mellitus
Outcomes
Epidemiology
author_facet Santhi Mantravadi
Michael George
Colleen Brensinger
Min Du
Joshua F. Baker
Alexis Ogdie
author_sort Santhi Mantravadi
title Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
title_short Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
title_full Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
title_fullStr Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
title_full_unstemmed Impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
title_sort impact of tumor necrosis factor inhibitors and methotrexate on diabetes mellitus among patients with inflammatory arthritis
publisher BMC
series BMC Rheumatology
issn 2520-1026
publishDate 2020-09-01
description Abstract Background To determine whether initiation of a tumor necrosis factor inhibitor (TNFi) or methotrexate improves hemoglobin A1c in patients with psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ankylosing spondylitis (AS) who also have diabetes mellitus (DM). Methods A retrospective cohort study was conducted in Optum’s de-identified Clinformatics® Data Mart Database, an administrative claims database, using data from 2000 to 2014. Patients with PsA, RA, or AS, with DM (defined by ICD-9-CM codes) and/or HbA1c ≥7%, who newly initiated either a TNFi, MTX, or metformin (positive control) were identified. The change in HbA1c after drug initiation was calculated. Statistical differences in the change in HbA1c between drugs were assessed using the Wilcoxon rank sum test and linear regression models adjusting for potential confounders. Results Among 10,389 drug initiations in 9541 patients with PsA, RA, or AS, and available HbA1c values, HbA1c was ≥7 at baseline in 254 (35%) TNFi initiations, 361(37%) MTX initiations, and 2144 (50%) metformin initiations. Median HbA1c change was − 0.35 (IQR -1.10, 0.30) after TNFi initiation, − 0.40 (IQR -1.20, 0.30) after MTX initiation, and − 0.80 (IQR -1.60, − 0.10) after metformin initiation. In adjusted analyses, TNFi initiators had less of a decrease in HbA1c compared to MTX initiators (β 0.22, 95% CI: 0.004, 0.43), p = 0.046. Metformin initiators had a significantly greater decrease in HbA1c than MTX, β − 0.38 (95% CI: − 0.52, − 0.23), p < 0.001. Glucocorticoid use was not accounted for in the models. Conclusion HbA1c decreased with TNFi initiation or MTX initiation. Reductions in HbA1c after initiation of a TNFi or MTX are about half (~ 0.4 units) the decrease observed after initiation of metformin.
topic Psoriatic arthritis
Rheumatoid arthritis
Ankylosing spondylitis
Diabetes mellitus
Outcomes
Epidemiology
url http://link.springer.com/article/10.1186/s41927-020-00138-3
work_keys_str_mv AT santhimantravadi impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis
AT michaelgeorge impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis
AT colleenbrensinger impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis
AT mindu impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis
AT joshuafbaker impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis
AT alexisogdie impactoftumornecrosisfactorinhibitorsandmethotrexateondiabetesmellitusamongpatientswithinflammatoryarthritis
_version_ 1724768572984524800